Valeant Pharmaceuticals to acquire Private Formula - MarketLine Financial Deals

Valeant Pharmaceuticals to acquire Private Formula

Valeant Pharmaceuticals to acquire Private Formula - MarketLine Financial Deals
Valeant Pharmaceuticals to acquire Private Formula
Published Sep 30, 2009
2 pages — Published Sep 30, 2009
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Valeant Pharmaceuticals International (formerly ICN Pharmaceuticals, Inc.), a US-based specialty pharmaceutical company, has agreed to acquire Private Formula International Holdings Pty Limited.

  
Source:
Document ID
MA09911_091005
Country
Country
Ticker
VRX=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Valeant Pharmaceuticals to acquire Private Formula" Sep 30, 2009. Alacra Store. Dec 09, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Valeant-Pharmaceuticals-to-acquire-Private-Formula-2052-9556>
  
APA:
MarketLine Financial Deals. (2009). Valeant Pharmaceuticals to acquire Private Formula Sep 30, 2009. New York, NY: Alacra Store. Retrieved Dec 09, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Valeant-Pharmaceuticals-to-acquire-Private-Formula-2052-9556>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.